The November 6, 2026 hearing is the key catalyst. If the court validates the 2025 reverse split, the path to closing the Avere deal clears. If opposition emerges or the court denies validation, the deal timeline and stock validity face material risk. Monitor for any stockholder objections filed by the October 27, 2026 deadline.
Price Chart
Executive Summary
NextCure filed a Section 205 petition in Delaware Chancery Court seeking validation of its July 2025 reverse stock split (1:12 ratio), which was approved by ~90% of votes cast (64.76% of outstanding shares) but fell short of the 66 2/3% supermajority standard that a 2026 DGCL amendment suggests may have been required. The petition is a prerequisite to closing the pending business combination with Avere Therapeutics, targeted for November 2026, and the court has set a hearing for November 6, 2026. The filing is procedural and defensive — the company is proactively resolving a voting-standard ambiguity to avoid deal disruption.
Key Financial Metrics
Key Facts
- NextCure filed a Section 205 petition on September 14, 2026 to validate the 2025 Reverse Split Amendment, which was approved by 89.92% of votes cast (18,166,577 for, 2,028,946 against) but only 64.76% of outstanding shares, short of the 66 2/3% supermajority standard.
- A 2026 DGCL amendment effective August 1, 2026 created uncertainty about whether the supermajority standard should have applied, prompting the petition.
- The Delaware Court of Chancery set a hearing on the petition for November 6, 2026; the company wishes to close the Avere business combination in November 2026.
- The company has treated the 2025 reverse split as valid in subsequent financings: a Simcere subscription, a November 2025 PIPE (708,428 shares + 1,815,049 pre-funded warrants), and a $14.5M ATM offering.
- No stockholder has challenged the 2025 reverse split or its voting standard disclosure.
- The Merger Agreement with Avere requires NextCure to issue shares predicated on the validity of the 2025 reverse split; 4,068,951 shares were outstanding as of the relevant date.
Financial Impact
No direct financial impact; the petition seeks to validate existing capitalization. Failure could delay or block the Avere business combination, which the company states will generate substantial stockholder value.
Risk Factors
- Court could deny validation, creating uncertainty over all post-split capitalization and potentially blocking the Avere business combination.
- Stockholders could file opposition by October 27, 2026, introducing adversarial proceedings.
- Even if validated, the 2026 reverse split still requires supermajority approval, adding execution risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-110975 |
| Document: nxtc-20260915x425.htm | 0001104659-26-110975 |
| Document: 0001104659-26-110975-index-headers.html | 0001104659-26-110975 |
| Document: 0001104659-26-110975-index.html | 0001104659-26-110975 |
| Document: 0001104659-26-110975.txt | 0001104659-26-110975 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.72 (+5.06%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.72 (+15.08%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.72 (+13.62%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.72 (−13.15%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.72 (+13.15%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.72 (+69.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers